Actimed Therapeutics Appoints Dr. Anders Ullman to Board as It Advances Pipeline in Cancer Cachexia and Muscle Wasting
Key Insights
Actimed Therapeutics (search), a UK-based clinical stage specialty pharmaceutical company, has appointed Dr. Anders Ullman to its Board of Directors as of 30 July 2026.
Dr. Ullman brings over 30 years of pharmaceutical R&D and corporate leadership experience, having held senior roles at AstraZeneca, Bayer, Takeda, Baxter, and Sobi.
Actimed is advancing clinical programmes in cancer cachexia (search), obesity-related muscle loss, and other muscle wasting disorders, including S-pindolol (search) and S-oxprenolol (ACM-002).
Actimed Therapeutics (search) Ltd, a UK-based clinical stage specialty pharmaceutical company, announced on 30 July 2026 the appointment of Dr. Anders Ullman to its Board of Directors. The move comes as the company advances its clinical programmes targeting cancer cachexia (search), obesity-associated muscle loss, and other muscle wasting disorders — areas with significant unmet medical need and no globally approved therapies.
Dr. Ullman is a physician, clinical pharmacologist, and pharmaceutical executive with more than 30 years of international experience spanning drug discovery, development, and corporate leadership. He has held senior leadership positions across the global pharmaceutical industry, including Astra, AstraZeneca, Bayer, Biovitrum, Nycomed, Takeda, Baxter, and Sobi, where he most recently served as Head of Research & Development and Chief Medical Officer. Dr. Ullman earned his M.D. and Ph.D. from the University of Gothenburg and is a board-certified clinical pharmacologist. He has also served on the boards of several life science companies, including Verona Pharma.
"We are delighted to welcome Anders to the Board at an exciting stage in the Company's development," said Robin Bhattacherjee, CEO of Actimed. "His extensive experience in pharmaceutical R&D, clinical development and corporate leadership, together with his strong track record of bringing innovative medicines through development, will be invaluable as Actimed advances its clinical programmes in cancer cachexia (search), obesity and other muscle wasting disorders."
Dr. Ullman commented: "I am pleased to join the Board of Actimed at such an important time. The Company is developing innovative therapies that address significant unmet medical needs in muscle wasting disorders, an area with substantial clinical and commercial potential."
The Unmet Need in Muscle Wasting Disorders
Cachexia is a wasting disease associated with cancer and other serious chronic illnesses, characterised by severe weight loss, and is associated with significant morbidity and mortality. Despite its prevalence in cancer patients and its devastating clinical impact, there is currently no globally approved therapy for the treatment or prevention of cancer-related cachexia.
In the obesity setting, patients receiving GLP-1 receptor agonists for weight management can experience reductions in lean muscle mass alongside fat loss. Preserving muscle while achieving healthy weight reduction remains an important unmet need, highlighting the opportunity for novel approaches that support and preserve healthy body composition.
Actimed's Clinical Pipeline
Actimed Therapeutics (search) is focused on advancing muscle health through two key programmes. Previous studies with S-pindolol (search) have generated promising Phase 2a proof-of-concept data in cancer cachexia (search) patients, and the company has conducted a pharmacokinetic and pharmacodynamic (PK/PD) study of S-pindolol benzoate to characterise the benzoate salt of S-pindolol. Additionally, early non-clinical data confirm a potential role for S-pindolol benzoate in preserving muscle mass when used in combination with a GLP-1 agonist for weight loss.
Actimed also owns the global rights to S-oxprenolol (ACM-002), which is being developed to treat the muscle wasting and loss of body mass seen in amyotrophic lateral sclerosis (search) (ALS), where it may impact survival. The US Food and Drug Administration has granted Orphan Drug Designation to S-oxprenolol for the treatment of ALS.
Board Transition
Actimed also acknowledged the departure of Stefan Wohlfeil, who has stepped down from the Board. The company expressed gratitude for his valued contribution and support during his tenure.